Peptides News and Research

RSS

Researchers create protein molecule for new anti-inflammatory therapies

Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.

11 Mar 2011

SAP may serve as effective nanomaterial to prevent prostate cancer spread

When prostate cancer stem cells were enclosed in self-assembling nanomaterials made of peptides, the SAP stopped cancer stem cell colony formation and also stopped the division of cancer cells in laboratory cultures.

11 Mar 2011

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Pepscan Therapeutics, the Dutch biotechnology firm focusing on protein mimicry technology, today announces that it has signed a Research and License Agreement with Crucell Holland B.V. the Dutch developer of vaccines and antibodies.

10 Mar 2011

Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions

Compugen Ltd. announced today positive animal model results for CGEN-25068, a novel peptide predicted and selected in silico to block a specific protein-protein interaction known to play an important role in various immune-related disease conditions.

8 Mar 2011

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announced the award of €2 million in funding over 30 months from the « Fond Unique Interministériel » (a French program supporting collaborative research projects) including an amount of €743,000 specifically allocated to BioAlliance Pharma.

5 Mar 2011

Football player announces release of new pre-workout intensity supplement

Ray Lewis, one of the greatest players ever to step on a football field, today announced the release of an all new pre-workout intensity supplement, called Power Fuel, which will feature Lewis on its packaging and contain a powerful custom ingredient blend named in his honor.

5 Mar 2011

Researchers demonstrate potential neurochemical mechanism of weight loss

An interdisciplinary group of researchers at the University of Pennsylvania has, for the first time, identified the neurological and cellular signaling mechanisms that contribute to satiety - the sensation of feeling full - and the subsequent body-weight loss produced by drugs used to treat type 2 diabetes. More comprehensive knowledge of these mechanisms could form the basis for anti-obesity medications.

4 Mar 2011

Routine blood test can reduce hospital readmissions in patients with heart failure

An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals for the development of an active vaccination programme against Alzheimer's disease.

1 Mar 2011

Nile plans to develop novel therapeutics for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced plans to pursue a new indication in the field of heart failure.

1 Mar 2011

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals (GSK) for the development of an active vaccination programme against Alzheimer´s disease. While the lead vaccine candidate AD02 is currently in phase II clinical testing, two additional preclinical programmes have been completed successfully. The second programme was related to alternative vaccine candidates generated by AFFiRiS´ AFFITOME® technology, including candidate AD03. Based on the promising preliminary results of this programme, GSK exercised its option for the alternative vaccine candidates which triggered a EUR 2.5 million payment to AFFiRiS. An additional EUR 1 million payment became due simultaneously for the successful completion of tests of alternative vaccine formulations.

28 Feb 2011

Simpler method of making water-soluble short protein chains with spiral structures

Researchers have developed a simple method of making short protein chains with spiral structures that can also dissolve in water, two desirable traits not often found together. Such structures could have applications as building blocks for self-assembling nanostructures and as agents for drug and gene delivery.

25 Feb 2011

Unigene accelerates UGP281 anorexigenic peptide to treat obese patients

Unigene Laboratories, Inc. announced today that the Company is accelerating the development of its lead proprietary anorexigenic peptide, UGP281.

25 Feb 2011

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

25 Feb 2011

Study: Rare genetic mutations may provide clues to improve treatment for schizophrenia

Scientists are eyeing a rare genetic glitch for clues to improved treatments for some people with schizophrenia - even though they found the mutation in only one third of 1 percent of patients.

25 Feb 2011

Research: Gene mutation linked to schizophrenia may aid in new drug development

In a major advance for schizophrenia research, an international team of scientists led by the University of California, San Diego School of Medicine and involving Trinity College Dublin researchers has identified a gene mutation strongly linked to schizophrenia that may be an important new target for the development of drug therapies.

24 Feb 2011

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

24 Feb 2011

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.

23 Feb 2011

Signaling mechanism in bacterial ribosome linked to antibiotic resistance

Researchers at the University of Illinois at Chicago have discovered a signaling mechanism in the bacterial ribosome that detects proteins that activate genes for antibiotic resistance.

23 Feb 2011

Peptides News and Research

Researchers create protein molecule for new anti-inflammatory therapies

SAP may serve as effective nanomaterial to prevent prostate cancer spread

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

Football player announces release of new pre-workout intensity supplement

Researchers demonstrate potential neurochemical mechanism of weight loss

Routine blood test can reduce hospital readmissions in patients with heart failure

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

Nile plans to develop novel therapeutics for ADHF

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

Simpler method of making water-soluble short protein chains with spiral structures

Unigene accelerates UGP281 anorexigenic peptide to treat obese patients

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Study: Rare genetic mutations may provide clues to improve treatment for schizophrenia

Research: Gene mutation linked to schizophrenia may aid in new drug development

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Signaling mechanism in bacterial ribosome linked to antibiotic resistance

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News